Literature DB >> 27813409

β-Arrestin-Biased Agonists of the GLP-1 Receptor from β-Amino Acid Residue Incorporation into GLP-1 Analogues.

Marlies V Hager1, Lisa M Johnson1, Denise Wootten2, Patrick M Sexton2, Samuel H Gellman1.   

Abstract

Activation of a G protein-coupled receptor (GPCR) causes recruitment of multiple intracellular proteins, each of which can activate distinct signaling pathways. This complexity has engendered interest in agonists that preferentially stimulate subsets among the natural signaling pathways ("biased agonists"). We have examined analogues of glucagon-like peptide-1 (GLP-1) containing β-amino acid residues in place of native α residues at selected sites and found that some analogues differ from GLP-1 in terms of their relative abilities to promote G protein activation (as monitored via cAMP production) versus β-arrestin recruitment (as monitored via BRET assays). The α → β replacements generally cause modest declines in stimulation of cAMP production and β-arrestin recruitment, but for some replacement sets cAMP production is more strongly affected than is β-arrestin recruitment. The central portion of GLP-1 appears to be critical for achieving bias toward β-arrestin recruitment. These results suggest that backbone modification via α → β residue replacement may be a versatile source of agonists with biased GLP-1R activation profiles.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27813409      PMCID: PMC5207657          DOI: 10.1021/jacs.6b08323

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  46 in total

1.  Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) differentially regulates orthosteric but not allosteric agonist binding and function.

Authors:  Cassandra Koole; Denise Wootten; John Simms; Emilia E Savage; Laurence J Miller; Arthur Christopoulos; Patrick M Sexton
Journal:  J Biol Chem       Date:  2011-12-06       Impact factor: 5.157

2.  Refinement of glucagon-like peptide 1 docking to its intact receptor using mid-region photolabile probes and molecular modeling.

Authors:  Laurence J Miller; Quan Chen; Polo C-H Lam; Delia I Pinon; Patrick M Sexton; Ruben Abagyan; Maoqing Dong
Journal:  J Biol Chem       Date:  2011-03-16       Impact factor: 5.157

3.  Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening.

Authors:  Cassandra Koole; Denise Wootten; John Simms; Celine Valant; Rohan Sridhar; Owen L Woodman; Laurence J Miller; Roger J Summers; Arthur Christopoulos; Patrick M Sexton
Journal:  Mol Pharmacol       Date:  2010-06-14       Impact factor: 4.436

4.  Emergent biological properties of arrestin pathway-selective biased agonism.

Authors:  Kathryn M Appleton; Louis M Luttrell
Journal:  J Recept Signal Transduct Res       Date:  2013-02-28       Impact factor: 2.092

5.  Beta-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic beta cells.

Authors:  Noriyuki Sonoda; Takeshi Imamura; Takeshi Yoshizaki; Jennie L Babendure; Juu-Chin Lu; Jerrold M Olefsky
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-29       Impact factor: 11.205

6.  Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides.

Authors:  K Hupe-Sodmann; G P McGregor; R Bridenbaugh; R Göke; B Göke; H Thole; B Zimmermann; K Voigt
Journal:  Regul Pept       Date:  1995-08-22

7.  GLP-1 mediates antiapoptotic effect by phosphorylating Bad through a beta-arrestin 1-mediated ERK1/2 activation in pancreatic beta-cells.

Authors:  Julie Quoyer; Christine Longuet; Christophe Broca; Nathalie Linck; Safia Costes; Elodie Varin; Joël Bockaert; Gyslaine Bertrand; Stéphane Dalle
Journal:  J Biol Chem       Date:  2009-11-13       Impact factor: 5.157

Review 8.  Therapeutic potential of β-arrestin- and G protein-biased agonists.

Authors:  Erin J Whalen; Sudarshan Rajagopal; Robert J Lefkowitz
Journal:  Trends Mol Med       Date:  2010-12-21       Impact factor: 11.951

Review 9.  Physiology and emerging biochemistry of the glucagon-like peptide-1 receptor.

Authors:  Francis S Willard; Kyle W Sloop
Journal:  Exp Diabetes Res       Date:  2012-05-14

10.  Selective VIP Receptor Agonists Facilitate Immune Transformation for Dopaminergic Neuroprotection in MPTP-Intoxicated Mice.

Authors:  Katherine E Olson; Lisa M Kosloski-Bilek; Kristi M Anderson; Breha J Diggs; Barbara E Clark; John M Gledhill; Scott J Shandler; R Lee Mosley; Howard E Gendelman
Journal:  J Neurosci       Date:  2015-12-16       Impact factor: 6.167

View more
  29 in total

1.  Impact of Substitution Registry on the Receptor-Activation Profiles of Backbone-Modified Glucagon-like Peptide-1 Analogues.

Authors:  Brian P Cary; Marlies V Hager; Samuel H Gellman
Journal:  Chembiochem       Date:  2019-09-20       Impact factor: 3.164

2.  Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury.

Authors:  Elliot J Glotfelty; Thomas Delgado; Luis B Tovar-Y-Romo; Yu Luo; Barry Hoffer; Lars Olson; Tobias Karlsson; Mark P Mattson; Brandon Harvey; David Tweedie; Yazhou Li; Nigel H Greig
Journal:  ACS Pharmacol Transl Sci       Date:  2019-02-11

3.  Evaluation of β-Amino Acid Replacements in Protein Loops: Effects on Conformational Stability and Structure.

Authors:  David E Mortenson; Dale F Kreitler; Nicole C Thomas; Ilia A Guzei; Samuel H Gellman; Katrina T Forest
Journal:  Chembiochem       Date:  2018-02-13       Impact factor: 3.164

4.  Oleoylethanolamide modulates glucagon-like peptide-1 receptor agonist signaling and enhances exendin-4-mediated weight loss in obese mice.

Authors:  Jacob D Brown; Danielle McAnally; Jennifer E Ayala; Melissa A Burmeister; Camilo Morfa; Layton Smith; Julio E Ayala
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2018-06-27       Impact factor: 3.619

Review 5.  Neurochemical regulators of food behavior for pharmacological treatment of obesity: current status and future prospects.

Authors:  Gayane Sargis Vardanyan; Hasmik Samvel Harutyunyan; Michail Iosif Aghajanov; Ruben Sargis Vardanyan
Journal:  Future Med Chem       Date:  2020-10-12       Impact factor: 3.808

Review 6.  Advances in therapeutic peptides targeting G protein-coupled receptors.

Authors:  Anthony P Davenport; Conor C G Scully; Chris de Graaf; Alastair J H Brown; Janet J Maguire
Journal:  Nat Rev Drug Discov       Date:  2020-03-19       Impact factor: 84.694

7.  Characterization of signal bias at the GLP-1 receptor induced by backbone modification of GLP-1.

Authors:  Marlies V Hager; Lachlan Clydesdale; Samuel H Gellman; Patrick M Sexton; Denise Wootten
Journal:  Biochem Pharmacol       Date:  2017-03-29       Impact factor: 5.858

8.  Phase-plate cryo-EM structure of a biased agonist-bound human GLP-1 receptor-Gs complex.

Authors:  Yi-Lynn Liang; Maryam Khoshouei; Alisa Glukhova; Sebastian G B Furness; Peishen Zhao; Lachlan Clydesdale; Cassandra Koole; Tin T Truong; David M Thal; Saifei Lei; Mazdak Radjainia; Radostin Danev; Wolfgang Baumeister; Ming-Wei Wang; Laurence J Miller; Arthur Christopoulos; Patrick M Sexton; Denise Wootten
Journal:  Nature       Date:  2018-02-21       Impact factor: 49.962

Review 9.  Structural Basis for Allosteric Modulation of Class B G Protein-Coupled Receptors.

Authors:  Denise Wootten; Laurence J Miller
Journal:  Annu Rev Pharmacol Toxicol       Date:  2019-08-27       Impact factor: 13.820

10.  Molecular Mechanisms of Class B GPCR Activation: Insights from Adrenomedullin Receptors.

Authors:  Michael L Garelja; Maggie Au; Margaret A Brimble; Joseph J Gingell; Erica R Hendrikse; Annie Lovell; Nicole Prodan; Patrick M Sexton; Andrew Siow; Christopher S Walker; Harriet A Watkins; Geoffrey M Williams; Denise Wootten; Sung H Yang; Paul W R Harris; Debbie L Hay
Journal:  ACS Pharmacol Transl Sci       Date:  2020-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.